Acorn Cardiovascular Inc., which has struggled for years to convince the Food and Drug Administration to approve its heart device, will need to either raise more money or sell the company, MedCity News has learned. In an e-mail, Acorn president Steve Anderson said the company already has slashed costs, including shutting down its website and moving out of its headquarters in New Brighton, Minnesota.
As a journalist, I’m frequently beset with impulsive self-righteousness. Which is why I jumped the gun a bit this week. I wanted to attend the Med Tech Investment conference in Minneapolis this past week, specifically a speech by Dr. Dan Schultz, the former head of the Center for Devices and Radiological Health (CDRH) at the […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.